Jacobs Asset Management Increased By $2.46 Million Its Signature Bk New York N Y (SBNY) Stake; Shorts at Cytosorbents (CTSO) Raised By 1.27%

February 21, 2018 - By Ellis Scott

Cytosorbents Corporation (NASDAQ:CTSO) had an increase of 1.27% in short interest. CTSO’s SI was 1.33 million shares in February as released by FINRA. Its up 1.27% from 1.31M shares previously. With 97,800 avg volume, 14 days are for Cytosorbents Corporation (NASDAQ:CTSO)’s short sellers to cover CTSO’s short positions. The SI to Cytosorbents Corporation’s float is 5.7%. The stock increased 8.35% or $0.61 during the last trading session, reaching $7.91. About 898,547 shares traded or 528.38% up from the average. Cytosorbents Corporation (NASDAQ:CTSO) has declined 4.26% since February 21, 2017 and is downtrending. It has underperformed by 20.96% the S&P500.

Jacobs Asset Management Llc increased Signature Bk New York N Y (SBNY) stake by 64% reported in 2017Q3 SEC filing. Jacobs Asset Management Llc acquired 19,200 shares as Signature Bk New York N Y (SBNY)’s stock declined 12.57%. The Jacobs Asset Management Llc holds 49,200 shares with $6.30 million value, up from 30,000 last quarter. Signature Bk New York N Y now has $8.26B valuation. The stock increased 1.88% or $2.839 during the last trading session, reaching $153.919. About 161,231 shares traded. Signature Bank (NASDAQ:SBNY) has risen 4.47% since February 21, 2017 and is uptrending. It has underperformed by 12.23% the S&P500.

Since January 8, 2018, it had 0 insider buys, and 2 sales for $332,500 activity. BLOCH KATHLEEN P. sold 32,400 shares worth $236,400.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $226.93 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Investors sentiment increased to 1.27 in Q3 2017. Its up 0.54, from 0.73 in 2017Q2. It increased, as 8 investors sold Cytosorbents Corporation shares while 3 reduced holdings. 6 funds opened positions while 8 raised stakes. 2.38 million shares or 26.98% more from 1.87 million shares in 2017Q2 were reported. Geode Cap Management Limited Liability, a Massachusetts-based fund reported 127,125 shares. Skylands Cap Lc accumulated 0.41% or 500,050 shares. Grp One Trading Ltd Partnership has 254 shares. Northern Trust Corp, a Illinois-based fund reported 48,765 shares. Thompson Davis And Com holds 1,000 shares or 0.01% of its portfolio. Morgan Stanley holds 0% in Cytosorbents Corporation (NASDAQ:CTSO) or 6,862 shares. 136,817 were reported by Blackrock Inc. Manatuck Hill Ptnrs Ltd Limited Liability Company has 150,000 shares. Vanguard Gru Inc Inc invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Fincl Bank Of New York Mellon invested in 0% or 25,519 shares. Fortaleza Asset Management Inc owns 23,375 shares for 0.27% of their portfolio. Wells Fargo & Mn accumulated 7,414 shares or 0% of the stock. Aviance Cap Limited Liability Com invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Royal Commercial Bank Of Canada has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 2,805 shares. Pnc Fincl Ser Group Inc reported 20,000 shares or 0% of all its holdings.

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 13 analyst reports since October 29, 2015 according to SRatingsIntel. WBB Securities upgraded the stock to “Buy” rating in Thursday, October 29 report. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, September 26. The firm has “Buy” rating by Maxim Group given on Wednesday, July 5. The firm has “Buy” rating by Maxim Group given on Tuesday, August 8. The rating was initiated by B. Riley & Co on Friday, October 7 with “Buy”. As per Tuesday, May 24, the company rating was initiated by Maxim Group. The rating was initiated by Aegis Capital on Wednesday, October 26 with “Buy”. On Tuesday, May 30 the stock rating was maintained by Aegis Capital with “Buy”. The firm earned “Buy” rating on Tuesday, January 9 by H.C. Wainwright. The rating was maintained by Maxim Group on Monday, July 17 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: